Centro de Oncologia de Precision

The trials here

What the 4 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials

Phase

• Phase 33 trials
• Phase 21 trial

Status

• Active, not recruiting2 trials
• Recruiting2 trials

Lead sponsor

• Bristol-Myers Squibb2 trials
• Immutep S.A.S.1 trial
• Regeneron Pharmaceuticals1 trial

Running trials

• Recruiting

  A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

  NCT07361497· Phase 3· Bristol-Myers Squibb· Source

  Contact: Pamela Salman Boghikian, Site 0855

• Recruiting

  A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)

  NCT07361510· Phase 3· Bristol-Myers Squibb· Source

  Contact: Pamela Salman Boghikian, Site 0302

• Active, not recruiting

  Study of Eftilagimod Alfa (Efti) in Combination With Pembrolizumab and Chemotherapy Versus Placebo in Combination With Pembrolizumab and Chemotherapy in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) (TACTI-004)

  NCT06726265· Phase 3· Immutep S.A.S.· Source

• Active, not recruiting

  A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

  NCT06161441· Phase 2· Regeneron Pharmaceuticals· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer2 recruiting